SOURCE: Predicine Inc

Predicine Inc

April 18, 2016 08:00 ET

Predicine, CloudHealth Form Strategic Partnership on Liquid Biopsy Cancer Tests

HAYWARD, CA--(Marketwired - Apr 18, 2016) - Predicine, Inc. (Predicine) and Shanghai-based firm, CloudHealth Genomics, Ltd. (CloudHealth) today announced an agreement to jointly promote Predicine's next-generation sequencing (NGS)-based liquid biopsy diagnostic tests in the China oncology market.

Under this partnership, Predicine will introduce PrediSeq, its cell-free DNA (cfDNA) NGS diagnostic tests for the oncology space in mid-2016, with a portfolio of additional tests for other cancer indications launching in the upcoming year. CloudHealth will provide clinical genetic testing infrastructure and high-end and high-throughput sequencing capacity.

"Predicine is very excited to collaborate with CloudHealth to bring the world-class liquid biopsy products to serve cancer patients and support global drug development," said Shidong Jia, Predicine's Founder and CEO. "We are committed to developing strategic partnerships with academic and industry leaders who share our vision of improving and innovating the global healthcare ecosystem." Following their B2B business model, Predicine has developed a one-stop solution package of liquid biopsy precision diagnostics, ranging from sample collection, nucleic acid extraction, library preparation, target enrichment, bioinformatics and data analysis.

"Liquid biopsy cancer testing is being widely adopted and implemented in America, and we hope to promote it as a standard practice in hospitals throughout China as part of this strategic partnership with CloudHealth," Predicine's President, Winston Patrick Kuo added. "The launch of our PrediSeq cancer panels is timely with the recent announcement of the Precision Medicine initiative and the unmet medical need of liquid biopsy test in China. We are proud of our cfDNA NGS molecular diagnostic test's ability to greatly detect and monitor cancer through diagnosis of conditions that often go misdiagnosed for years."

"NGS liquid biopsy is central to CloudHealth's strategy to advance personalized healthcare and cancer diagnostics. CloudHealth is very excited to collaborate with Predicine to expand our NGS capacity and bring the best precision diagnostics products to cancer patients and drug development industry," Jason Jin, CEO and Co-founder of CloudHealth, said in a statement. Shanghai-based CloudHealth is among the first batch of firms in China to purchase Illumina HiSeq X Ten high throughput sequencing system and has one of the largest sequencing capacity in China."

Specific terms of the arrangement were not disclosed.

About Predicine
Predicine, Inc based in Hayward, CA, is an international "big data" precision medicine organization that is committed to developing and commercializing the first- and best-in-class precision diagnostics, which includes a non-invasive cancer diagnostics solution, a comprehensive multiplex biomarker service platform and precision medicine portfolio to address the unmet medical needs in China and globally. Visit to learn more.

About CloudHealth
CloudHealth Genomics Ltd based in Shanghai, China, is a high-tech company and pioneer in China on genomics sequencing for preventive medicine and precision medicine. CloudHealth owns the whole genome sequencing platform of HiSeq X10, Clinic Genetic Test Lab, High-End Clinic Center, Big Data Center, Genomics Research Institute, Life Center, Medical Doctor's Alliance, and Academician Workstation. CloudHealth has an international team of nearly 100 scientists in life science and bioinformatics fields led by well known world experts. CloudHealth has established an integrated big health and precision medicine service chain including whole genome sequencing, genetic testing, premium examination, health counseling, health management and precision medicine. Visit to learn more. 

Contact Information